BioWorld

Dec. 22, 2008

Ignoring Shareholders Puts Industry Investment at Risk

Back in early October, the future was looking pretty good for Avigen Inc. Its stock was trading above $3 and it was awaiting data on lead program AV562, with plans for additional pipeline programs down the road. Read More

Money Raised Year to Date

Stock Winners and Losers For The Week

Biotechnology Company Deals with Other Biotechnology Companies: Oct. 24 - Dec. 18, 2008

Biotechnology Company Deals with Miscellaneous Companies: Oct. 24 - Dec. 18, 2008

Manufacturing, Marketing and Distribution Agreements Between Biotech Companies: Oct. 24 - Dec. 18, 2008

Biotech-Biotech Collaborations: Modified Agreements: Oct. 24 - Dec. 18, 2008

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...